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Osteoarthritis (OA)S100 proteins are low molecular weight calcium binding proteins expressed in vertebrates. The family consti-
tutes 21 knownmembers that are expressed in several tissues and cell types and play amajor role in various cel-
lular functions. Uniquely,members of the S100 family have both intracellular and extracellular functions. Several
members of the S100 family (S100A1, S100A2, S100A4, S1008, S100A9, S100A11, and S100B) have been identi-
ﬁed in human articular cartilage, and their expression is upregulated in diseased tissue. These S100 proteins elicit
a catabolic signaling pathway via receptor for advanced glycation end products (RAGE) in cartilage andmay pro-
mote progression of arthritis. This review summarizes our current understanding of the role of S100 proteins in
cartilage biology and in the development of arthritis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction: S100 family of proteins
S100 protein was ﬁrst discovered by Moore in brain tissue and
named “S100-protein” because it was soluble in 100% saturated ammo-
nium sulfate [1]. However, subsequent studies have shown that this
fraction contained two related proteins, S100A and S100B [2]. Currently,
the family of S100 proteins is comprised of 21 knownmembers that are
characterized by the presence of two EF-hand domains (calcium bind-
ing), one at each N-terminus and C-terminus separated by a hinge re-
gion. The carboxyl-terminal (c-terminus) EF-hand domain is referred
to as the conical (higher afﬁnity) calcium binding loop that encom-
passes 12 amino acids, whereas the low afﬁnity N-terminal loop formed
of 14 amino acids is known as the “pseudo” or S100-speciﬁc EF-hand
domain [3,4]. In humans, most S100 genes are clustered at chromosom-
al locus 1q21 except S100B, S100p and S100Z, which are mapped at
chromosomes 12q22, 4 and 5 [5–8]. Members of the S100 protein fam-
ily have sequence homology between 22 and 57%withmarked variance
at the hinge region and C-terminus, which is thought to contribute to
the diversity in their biological function [6]. S100 proteins are expressed
in various tissues in a cell type-speciﬁc manner and with speciﬁc sub-
cellular localization [9,10].
In the cell, S100 proteins exist as dimers (homodimers or hetero-
dimers) or multimers [11–13] wherein the monomeric units of S100
proteins are held together by non-covalent bonds [14–16]. The only
exception to this rule is S100G, which always exists as a monomer
[17,18]. In addition, multimerization of S100 protein is also promoted
by posttranslational modiﬁcation of monomeric S100 proteins [19]l rights reserved.and by binding of metal ions [11,12,20]. S100 proteins bind various
divalent metal ions, including calcium (high afﬁnity), zinc, and cop-
per [21–27]. Binding of these ions to S100 protein also modulates
their function by altering conformational changes. In the calcium-
free state, the EF-hand in each monomer is in anti-parallel conﬁrma-
tion. Upon calcium binding, each S100 monomer opens up to accom-
modate a target; the S100 dimer can bind target proteins on opposite
sides. Although S100 dimers are characterized by the same structural
motif, differences in the primary sequence of individual helices, the
hinge region, or the C-terminal region, as well as differences in the
inter-helical angles in calcium-loaded dimers, may be important for
the recognition of target proteins and speciﬁcation of functional
roles of individual S100 members.
2. Biological functions of S100 proteins
S100 proteins play a major role in a broad array of biological func-
tions. They have both intracellular and extracellular functions. Their
intracellular functions include modulation of enzyme activity, calci-
um homeostasis, cell growth and mobility, cell cycle regulation, cell
differentiation and cell survival [28]. Extracellularly, S100 proteins in-
teract with cell surface receptors, including receptor for advance gly-
cation end products (RAGE) [28–30] and toll-like receptors (TLR)
[31,32] and participate in signal transduction.
S100 proteins lack intrinsic enzymatic activity, but they partici-
pate in biological function via protein–protein interaction and modu-
lating the activity of their target molecule. Binding of S100B to
nuclear Dbf2-related protein kinase (NDR kinase) directly blocks the
recruitment of substrate on NDR kinase [33]. A similar mechanism
has been proposed for S100A4-mediated regulation of MetAP2 activ-
ity [34]. On the other hand, binding of S100A1 to ryanodine receptor,
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afﬁnity for ryanodine (its ligand) several fold, resulting in opening
of the RyR channel and increased release of calcium from the sarco-
plasmic reticulum in skeletal muscle [35], thus inﬂuencing intracellu-
lar calcium homeostasis.
Furthermore, studies have shown that multiple members of S100
family can interact with a speciﬁc target molecule and have differen-
tial effects. For example, S100A1, S100B, S100A4, and S100A11 are
known to interact directly with cytoskeletal elements including
microtubilin, microﬁlaments, intermediate ﬁlaments, actin, myosin,
tropomyosin; regulating cytoskeletal dynamics; and playing a role
in cell mobility and proliferation [28,36–38]. Likewise, many S100
proteins, including S100A2, S100A4, and S100B, interact with tumor
suppressor 53 (p53) and modulate its activity differentially. Binding
of S100A4 and S100B to p53 negatively modulates its activity to
cause cell growth arrest and apoptosis [39–41], whereas binding of
S100A2 enhances p53's transcriptional activity [42]. Binding of multi-
ple S100 proteins to a single target protein is not surprising given the
signiﬁcant homology in their primary sequence, and provides the
mechanism for the similar functional role of the two different S100
proteins in different tissues. On the other hand, the differential affects
of S100 proteins on the function of a single target protein also could
explain functional diversity within a given tissue.
Some members of the S100 protein family are released into the
extracellular environment, where they act as cytokines and are in-
volved in cell proliferation and survival, cell migration, and inﬂamma-
tion [28,29,43–47]. These functions of S100 proteins are associated
with numerous human pathologies, including cancer [48], neurode-
generative diseases such as Alzheimer's disease [49,50], autoimmune
diseases, and arthritis [51]. Thus, S100 proteins have garnered signif-
icant interest as potential therapeutic targets for various human
disorders.3. S100 proteins in cartilage
Cartilage is an avascular connective tissue present in the ear, nose,
rib cage, intervertebral disks, and joints. Articular cartilage lines the
end of bones in the joints. It provides smooth, frictionless movements
of joints and helps distribute the load across the joints. Articular car-
tilage is made up of collagens (mainly collagen type II), aggrecan,
large proteoglycans, and small biglycans. This matrix provides both
tensile strength and ﬂexibility to the tissue. Chondrocytes are the
sole cellular component of the cartilage tissue responsible for carti-
lage homeostasis (matrix synthesis and repair). However, in arthritis
(both rheumatoid arthritis [RA] and osteoarthritis [OA]), there is pro-
gressive loss of cartilage due to increased production of matrix-
degrading enzymes (e.g. matrix metalloproteinases [MMPs] and
aggrecanases) locally produced by chondrocytes in response to vari-
ous catabolic stimuli. In RA, a large proportion of matrix-degrading
enzymes come from the rheumatoid synovium, and chondrocytes
also participate in the RA disease process at sites remote from the car-
tilage–pannus junction. Extracellular S100 proteins behave like cyto-
kines and activate the RAGE signaling pathway, resulting in increased
production of matrix-degrading enzymes, including MMPs and a dis-
integrin and metalloproteinase with thrombospondin motifs
(ADAMTSs), which are involved in cartilage degradation and the de-
velopment of arthritis.
S100 protein in chondrocytes was ﬁrst identiﬁed by Stefansson et
al. [52] in human adult and fetal tissue using immunohistochemistry;
they found S100 protein staining in both the cytoplasm and the nu-
cleus. Subsequently, several groups have identiﬁed S100 protein in
normal tissue and in tumors of cartilage and bone [53–56]. In earlier
work, S100 protein was primarily studied as a marker for chondrocy-
tic phenotype and/or chondrogenic origin [55,57,58]. However, addi-
tional studies have reported that the intensity of S100 proteinincreases in chondrocytes near cartilage lesions and suggested that
S100 protein may be involved in the cartilage repair process.
Weiss and Dorfman [59] found that chondrocytes from different
regions in cartilage lesions stained differently for S100 protein. Cells
from degenerating and hypertrophic zones were stained strongly for
S100 protein compared to proliferating columnar chondrocytes. Sim-
ilarly, in osteoarthritic cartilage, S100 protein staining was seen in de-
generative and osteophytic regions of cartilage compared to
unaffected regions of cartilage [60], suggesting that S100 protein
may be involved in cartilage calciﬁcation and mineralization. Wolff
et al. [61] and Leonardi et al. [62] postulated that the presence of
S100 protein in the cells near cartilage damage indicates that
chondrocyte-like cells participate in early matrix repair. This notion
of S100-positive cells in matrix repair was further supported by two
independent studies. Itoi [63] reported that increased S100 protein
staining in cultured cartilage cells related to production of type II col-
lagen. In the second study, Sugimoto et al. [64] showed that fewer
cells stained positive for S100 protein in mild OA compared to moder-
ate and severe OA. In mild OA, S100 protein staining was present in
chondrocytes near the erosion of surface layers, whereas in severe
OA, S100-positive cells were found in clusters. Based on these ﬁnd-
ings, the authors speculated that S100 protein could inﬂuence meta-
bolic activity of cartilage matrix. These early studies suggested that
S100 protein might be involved in cartilage matrix synthesis and re-
pair. However, further studies are required to understand the molec-
ular mechanism involved. When these earlier studies were
performed, the S100 protein was thought to be a single protein. How-
ever, later studies have shown that the S100 protein fraction contains
a number of structurally related proteins, which collectively form a
family of S100 proteins.
Lately, there has been a renewed interest in S100 protein and its
function in chondrocytes due to identiﬁcation of multiple members
of S100 proteins in the cartilage and synovial ﬂuid of patients with
OA and RA, and their ability to activate RAGE. RAGE is a transmem-
brane receptor of the immunoglobulin superfamily that has been im-
plicated in several chronic diseases, including atherosclerosis,
diabetes, Alzheimer's disease, and arthritis. RAGE was identiﬁed in
cartilage and its expression is upregulated in diseased cartilage
[65,66]. Here, we summarize the function of various S100 proteins
identiﬁed in cartilage to date.
3.1. S100B
S100B was one of the ﬁrst members of the S100 family of proteins
detected in cartilage [61]. However, its role in cartilage biology is not
clearly understood. Recently, we have shown that extracellular S100B
stimulates the RAGE signaling pathway in chondrocytes, resulting in
activation of ERK and NF-κB signaling molecules and increased pro-
duction of MMP-13 [30]. These data suggest that extracellular S100B
is a pro-catabolic, pro-inﬂammatory factor that promotes cartilage
degradation and has a role in the pathogenesis of OA and RA.
3.2. S100A2
S100A2 is a homodimeric protein that requires both calcium and
zinc divalent metals for its activity. S100A2 was detected in both in-
tracellular (chondrocytes) and extracellular (cartilage matrix) tissues.
Extracellular cartilage matrix staining was conﬁned to the calcifying
areas of the epiphyseal cartilage [67], suggesting that S100A2 may
be involved in calciﬁcation of cartilage.
3.3. S100A4
S100A4, also known as metastasin (Mts-1), ﬁbroblast-speciﬁc pro-
tein (FSP1), p9ka, CAPL, and calvasculin, plays an important role in
metastasis. We and others have shown that S100A4 is expressed in
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in RA and OA [30,68]. S100A4 has both extracellular and intracellular
functions. We have recently shown that chondrocytes secrete S100A4
in response to external stimuli [69] and that S100A4 secretion is inde-
pendent of the Golgi-endoplasmic reticulum secretory pathway [69].
Extracellular S100A4 stimulates chondrocytes by activating RAGE sig-
naling, leading to increased matrix metalloproteinase-13 (MMP-13)
[30]. In addition, we found that S100A4 translocated into the nucleus
upon interleukin-1β (IL-1β) stimulation, and translocation required
post-translational modiﬁcation of S100A4 by the SUMO protein at
K22 and K96. Nuclear S100A4 (nS100A4) was associated with the pro-
moter region of MMP-13 in IL-1β-treated cells, suggesting that
nS100A4 is a key factor in transcriptional regulation of the MMP-13
gene. Mutation of the SUMO moiety accepting lysine residues abol-
ished the ability of S100A4 to be sumoylated and to translocate into
the nucleus [70]. Blocking of sumoylation and nuclear transport of
S100A4 inhibited the IL-1β-induced production of MMP-13. Taken to-
gether, these studies suggest that both extracellular and intracellular
S100A4 protein is involved in cartilage degradation and in the patho-
physiology of OA.
3.4. S100A8/S100A9
The alarmins S100A8 (MRP8) and S100A9 (MRP14) are abundant-
ly expressed in myeloid cells and play a major role in inﬂammation. In
joint tissues, S100A8 and A9 are expressed in synovium, bone, and
cartilage [71]. In cartilage, S100A8 and S100A9 expression is restrict-
ed to non-proliferative hypertrophic chondrocytes [71] and thought
to play a major role in calciﬁcation of the cartilage matrix. S100A8 ex-
pression is barely detectable in resting and unstimulated chondro-
cytes; however, pro-inﬂammatory cytokines such as TNFα, IL-1β,
and IL-17 upregulate chondrocyte S100A8 expression [72]. Increased
intracellular levels of S100A8 and S100A9 may lead to secretion of
these proteins into extracellular environments. Secretion of S100A8
and A9 has been shown in macrophages, but it is not known if chon-
drocytes secrete these proteins.
Studies have shown high levels of S100A8 and A9 in the synovial
ﬂuid obtained from patients with OA or RA. However, levels of
S100A8/A9 in synovial ﬂuid from RA patients are 10-fold higher
than in synovial ﬂuid from OA patients [73]. It is not clear if chondro-
cytes contribute to the levels of S100A8/A9 in synovial ﬂuid. Howev-
er, activated macrophages and neutrophils in the inﬂamed synovium
may contribute to increased levels of S100A8 and S100A9 proteins in
synovial ﬂuid from patients with OA and RA [74,75]. The extracellular
function of these alarmins is thought to occur via TLR-4 [32,76]. Chon-
drocytes express both RAGE and TLR-4 receptors. Chondrocytes re-
spond to extracellular S100A8/A9 stimulation by increasing the
production of matrix-degrading enzymes, including matrix metallo-
proteinase (MMP-2,-3,-9 and -13) and ADAMTS-4 and -5 in RAGE-
and TLR-4-independent pathways. These studies suggest that
S100A8 and S100A9 play an important role in cartilage degradation
via additional cell surface receptors.
Recently, Zreiqat et al. [77] showed that S100A8 and S100A9 ex-
pression is upregulated in early OA but not late OA, suggesting that
these alarmins may initiate initial cartilage degradation by upregulat-
ing MMPs and ADAMTSs. Deletion of S100A8/S100A9 prevented car-
tilage degradation in an antigen-induced arthritis model [78],
indicating that these proteins play a major role in cartilage degrada-
tion and development of inﬂammatory arthritis.
3.5. S100A11
S100A11, also known as S100C and calgizzarin, is a homodimeric
protein that interacts with annexin I in a calcium-dependent manner
and is a key protein in membrane organization [79,80]. In cartilage,
S100A11 expression is upregulated in OA and is thought to promotechondrocyte hypertrophy [65], characterized by a dysregulated ma-
trix repair process, increased expression collagen type X, and
matrix-degrading enzymes [65]. Chondrocytes releases S100A11 in
response to CXCL8, IL-1β, and TNF-α stimulation [19,65]. Extracellu-
lar S100A11 stimulates the RAGE-dependent signaling pathway,
resulting in activation of p-38 MAP kinase and increased production
of collagen type X, thereby promoting chondrocyte hypertrophy
[65]. The extracellular function of S100A11 is attributed to its ability
to form dimers. Cecil and Terkeltaub [19] reported that S100A11
monomers are covalently cross-linked by transamidation mediated
by transglutaminase 2 (TG-2). Mutants of S100A11 that cannot un-
dergo transamidation do not form dimers and fail to stimulate p38
MAP kinase signaling, but retain the capacity to interact with RAGE.
These studies suggest that post-translational modiﬁcation of
S100A11 by TG2 is an important step in S100A11-mediated chondro-
cyte hypertrophy and thus differentiation and progression of OA.
4. S100 proteins and signal transduction
Extracellular functions of several S100 proteins are mediated by
their interaction with RAGE, a member of the immunoglobulin super-
family expressed by diverse cell types, including chondrocytes [66].
Structurally, RAGE is composed of an extracellular domain (composed
of two ‘c’ type domains and one ‘v’ type domain), a trans-membrane
domain, and a short cytoplasmic domain [81]. Multiple isoforms of
RAGE have been identiﬁed [82] that are generated due to alternate
splicing of the RAGE gene [83]. The predominant forms of RAGE are
full-length RAGE, a secreted form of RAGE (sRAGE), C-truncated
RAGE (esRAGE), and an N-truncated RAGE. Chondrocytes express
several forms of RAGE, including full-length RAGE, N-truncated
RAGE and an unglycosylated form of RAGE [66], suggesting that mul-
tiple forms of RAGE may have specialized functions in cartilage tissue.
RAGE is activated bymultiple ligands including S100 proteins, AGEs
(advance glycation end products), amphoterin, amyloid-β, and lipo-
polysaccharide [81,84–86]. The ﬁrst step of RAGE activation involves in-
creased production of reactive oxygen species (ROS) via activation of
the NADPH oxidase complex [29,87]. ROS then activates and recruits a
cascade of signaling proteins, including RAS, Rac1/Cdc 42, MAP kinases
(ERK1/2, p-38 and JNK), phosphatidylinositol-3-kinase (PI3-K), AKT,
Janus kinase (JAK), and NF-κB. The signaling pathway activated by
RAGE depends on the kind of stimulus and cell type. Here, the focus is
on the RAGE signaling pathways activated by S100 proteins.
Binding of S100B to RAGE has been shown to activate the Ras–MEK–
ERK1/2–NF-κB pathway in neural cells, resulting in activation of small
GTPases, Rac1/Cdc 42 and neurite growth [88]. In addition, studies
have shown that S100B also activates the phosphatidylinositol-3-
kinase (PI3-K)–AKT pathway in a RAGE-dependent manner to in-
creased cellular proliferation [89]. However, at micromolar concentra-
tions, S100B protein activates RAGE and induces increased production
of ROS and release of cytochrome-C frommitochondria, leading to apo-
ptosis [88]. On the other hand, inmicroglia andmonocytes, activation of
RAGE by S100B results in activation of the Ras–Rac1/Cdc 42–JNK–AP-1
pathway, leading to upregulation of the pro-inﬂammatory enzyme
cyclo-oxygenase 2 (COX-2) [90,91]. In addition to activation of MAP
kinase-NF-κb pathways, stimulation of RAGE by S100B activates the
JAK–STAT pathway. In vascular smooth muscle cells, binding of S100B
protein to RAGE increases ROS production, which then recruits JAK2
and STAT 3, resulting in proliferation of vascular smooth muscle cells
[92]. RAGE-mediated activation of the JAK–STAT pathway required acti-
vation of non-receptor Src tyrosine kinase, protein kinase C, and phos-
pholipase D2 [92,93].
In chondrocytes, activation of RAGE by S100A4 increased ROS pro-
duction followed by the phosphorylation of Pyk-2, and activation of
MAP kinases, ERK1/2, p-38 and JNK and the transcription factor NF-
κB, resulting in increased production of MMP-13 [30]. Furthermore,
stimulation of RAGE by S100A11 activated MAP kinases p-38, and
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These studies suggest that RAGE signaling plays an important role in
the function of S100 proteins and their pathologies in cartilage. Howev-
er, in a murine model of mild or severe joint instability, knocking down
RAGE expression did not confer chondroprotection [94]. This result sug-
gests that S100 proteins in cartilage may engage other receptors for
their function, or that pathways activated by other receptors maymod-
ulate RAGE-S100 protein function in cartilage.
AGE-R1 (OST-48; oligosaccharyl transferase-4), a member of AGE
receptor complex consisting of AGE-R2 (80K-H phosphoprotein) and
AGE-R3 (galectin-3), was recently shown to negatively regulate
RAGE-mediated inﬂammatory response in mesangial cells [95]. The
study showed that RAGE-AGE-mediated activation of MAP kinases
(ERK1/2) and NF-κB was suppressed by overexpression of AGE-R1.
On the other hand, knockdown of AGE-R1 enhanced AGE-mediated
activation of MAP kinases (ERK1/2) and NF-κB more than twofold
[95]. AGE-R1 is expressed in chondrocytes (R. Yammani and R. Loeser,
unpublished observation), but its role in RAGE signaling and in chon-
drocyte biology is yet to be characterized. Interestingly, overexpres-
sion of CD36, a member of the class B scavenger receptor family
that is involved in clearing AGEs from cells [96], was recently
shown to suppress RAGE-S100A11-mediated catabolic functions in
chondrocytes [94]. The study found that CD-36 expression was locally
elevated at the site of cartilage lesions, and its expression was upre-
gulated by IGF-1 and the activation of peroxisome proliferator acti-
vated receptor-γ (PPARγ). Both IGF-1 and PPAR promote cartilageFig. 1. Biological roles of S100 proteins in cartilage. Increased expression of S100 proteins d
tracellular environment (red dashed lines). There, S100 proteins stimulate chondrocytes in
pathways causes chondrocyte hypertrophy and increased production of matrix-degrading en
of arthritis. Our recent study has shown that S100A4 translocates into the nucleus and prom
ized pathways in cartilage.anabolism, suggesting that CD36 expression may be chondroprotec-
tive and function opposite to RAGE. However, the role of CD 36 in car-
tilage and chondrocyte biology is not clearly understood.
CD36 is a multifunctional cell surface receptor expressed on many
cells, including chondrocytes. It binds to multiple ligands such as ox-
idized phospholipoprotein, AGEs, and long-chain fatty acids and
serves as an endocytic receptor [97–99]. It was ﬁrst identiﬁed as a re-
ceptor for the matrix protein thrombospondin-1 [100,101]. Binding of
oxidized LDL (oxLDL) to CD 36 elicits a cascade of signaling pathways
primarily involving the src family of non-receptor-bound tyrosine ki-
nases (fyn and Lyn) and MAP kinase (ERK1/2, p38 and JNK), which
then activates downstream pro-inﬂammatory genes [102–105]. Acti-
vation of CD 36 signaling pathways has been associated with numer-
ous human diseases associated with chronic inﬂammation, such as
atherosclerosis, thrombosis, Alzheimer's disease, and metabolic dis-
ease (type 2 diabetes) [106–109]. Interestingly, CD36 also serves as
a co-receptor for the toll-like receptor (TLR) family of cell surface re-
ceptors [110], which promote cartilage degradation and development
of both RA and OA. TLRs also share ligands (S100 and high-mobility
group box [HMGB] proteins) with RAGE.
Thus, initial overexpression of CD36 may act to scavenge toxic
proteins such as AGEs and S100 protein, and suppress RAGE signaling.
However, increases in these ligands may then activate RAGE and
TLRs, which then recruit CD36 into the mega-receptor complex, co-
promote the catabolic pathway, and play a major role in arthritis.
More studies are required to better understand the role of theseue to the activity of pro-inﬂammatory cytokines results in their secretion into the ex-
an autocrine or paracrine manner via RAGE or TLR. Activation of RAGE or TLR signaling
zymes (MMPs and ADAMTSs), which results in cartilage degradation and development
otes MMP-13 expression (blue dashed line). Question marks indicate still uncharacter-
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cartilage health and disease.
5. Conclusions and future perspectives
Although multiple members of the S100 protein family are
expressed in chondrocytes, very little is known about their biological
function in cartilage, especially their intracellular functions. Current
evidence suggests that S100 protein expression is upregulated in dis-
eased cartilage, and that these proteins promote cartilage degenera-
tion by activating RAGE signaling (Fig. 1). However, studies in other
cell types have suggested that RAGE is not a universal receptor for
S100 proteins [78,111–114], which may be true in chondrocytes as
well. A recent study [94] showed that the absence of RAGE expression
is not chondroprotective as expected, suggesting the role of an alter-
native S100 protein receptor. S100 proteins bind to other cell surface
receptors, including TLR, CD36 [115], and carboxylated glycans
[72,115], all of which are expressed by chondrocytes. Thus, further
studies are required to understand how S100 proteins are secreted
by chondrocytes, which receptors are activated by S100 proteins,
and the nature of their interactions to elucidate the role of S100 pro-
teins in cartilage biology. Identiﬁcation and characterization of these
molecular events will provide new and novel targets for therapies.
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